VMCO-1 is under clinical development by Nanoscope Therapeutics and currently in Phase II for Retinitis Pigmentosa (Retinitis). According to GlobalData, Phase II drugs for Retinitis Pigmentosa (Retinitis) have a 64% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how VMCO-1’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

VMCO-1 overview

VMCO-1 is under development for the treatment of juvenile macular degeneration (Stargardt Disease), dry age-related macular degeneration (geographic atrophy),  retinitis pigmentosa, usher syndrome and cone-rod dystrophy. It is administered by intravitreal route. The therapeutic candidate is a multi-characteristic broad-band light activatable white-opsin developed by MultiSite Gateway Technology. The technology uses a fusion Adeno-associated virus (AAV) vector with three plasmids encoding opsins with spectrally-separated activation peaks (ChR2 in blue, C1V1 in green and ReaChR in red).

Nanoscope Therapeutics overview

Nanoscope Therapeutics., is advancing gene therapy using light-sensitive molecules and light-assisted gene delivery for giving sight. The company is headquartered in United States.

For a complete picture of VMCO-1’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.